Skip to content

Rhythm Pharmaceuticals, Inc. RYTM Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Arrowhead Research logo
Arrowhead ResearchARWR
TG Therapeutics logo
TG TherapeuticsTGTX
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$6.64B+77.3%
Enterprise value$6.69B+78.4%
P/S30.6×+3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Rhythm Pharmaceuticals, Inc. (RYTM) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $278.49M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 33.6% year-over-year, from $208.39M to $278.49M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a 36.0% compound annual growth rate (CAGR), from $71.94M to $334.65M.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.